1 Result(s)

Article

HLA-DRB1*04:05 is involved in the development of Vogt–Koyanagi–Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) activate anti-tumor activity by inhibiting immune checkpoint molecules that suppress inflammatory T-cell activity. However, ICIs can initiate excessive immune responses, the...

Masaki Takeuchi, Akira Meguro, Jutaro Nakamura, Rei Chikagawa… in Scientific Reports (2023)